Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial

Brian S. Wojeck, Silvio E. Inzucchi, Ian J. Neeland, James P. Mancuso, Robert Frederich, Urszula Masiukiewicz, Nilo B. Cater, Darren K. McGuire, Christopher P. Cannon, Henry Klar Yaggi

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Purpose: The sodium-glucose transporter 2 inhibitor (SGLT2i) empagliflozin may reduce the incidence of obstructive sleep apnea (OSA) in patients with type 2 diabetes (T2D) and cardiovascular (CV) disease. This analysis of VERTIS CV, the CV outcome trial for the SGLT2i ertugliflozin conducted in a similar group of patients, explored the effects of ertugliflozin on reported incident OSA. Methods: In VERTIS CV, patients ≥ 40 years with T2D and atherosclerotic CV disease (ASCVD) were randomized to ertugliflozin 5 or 15 mg or placebo. The primary endpoint was the composite of major adverse CV events. This exploratory analysis evaluated the impact of ertugliflozin (5 and 15 mg pooled) on incident OSA. Patients with prevalent OSA were excluded. Incident OSA events were based on investigator-reported events using the MedDRA SMQ term “sleep apnea syndrome.” A multivariable Cox proportional hazards regression model was constructed to assess the association between ertugliflozin and incident OSA. Results: Of 8246 patients enrolled, 7697 (93.3%) were without baseline OSA (placebo, n = 2561; ertugliflozin, n = 5136; mean age 64.4 years; BMI 31.7 kg/m2; HbA1c, 8.2%; 69.2% male; 88.3% White). The OSA incidence rate was 1.44 per 1000 person-years versus 2.61 per 1000 person-years among patients treated with ertugliflozin versus placebo, respectively, corresponding to a 48% relative risk reduction (HR 0.52; 95% CI 0.28–0.96; P = 0.04). Conclusions: In VERTIS CV, ertugliflozin reduced by nearly half the incidence of OSA in patients with T2D and ASCVD. These data contribute to the literature that SGLT2is may have a significant beneficial impact on OSA. Trial registration. identifier: NCT01986881.

Original languageEnglish (US)
JournalSleep and Breathing
StateAccepted/In press - 2022
Externally publishedYes


  • OSA
  • SGLT2
  • Sleep apnea
  • Sleep disordered breathing
  • Sodium glucose transporter type 2 inhibitor

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Clinical Neurology


Dive into the research topics of 'Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial'. Together they form a unique fingerprint.

Cite this